Successful treatment of epilepsia partialis continua due to Rassmussen encephalitis with perampanel


Share / Export Citation / Email / Print / Text size:

Journal of Epileptology

Foundation of Epileptology

Subject: Medicine


eISSN: 2300-0147





Volume / Issue / page

Related articles

VOLUME 24 , ISSUE 1 (June 2016) > List of articles

Successful treatment of epilepsia partialis continua due to Rassmussen encephalitis with perampanel

Katja Göde / Annette Grossmann / Johannes Rösche *

Keywords : perampanel, Epilepsia Partialis Continua, Rasmussen encephalitis

Citation Information : Journal of Epileptology. Volume 24, Issue 1, Pages 67-70, DOI:

License : (CC BY 4.0)

Received Date : 14-December-2015 / Accepted: 18-March-2016 / Published Online: 31-March-2016



Background. Epilepsia partialis continua (EPC) is a difficult to treat condition, which tends to be refractory to antiepileptic drugs (AEDs). We previously published two other treatment episodes of EPC due to stroke and vascular dementia with a possible effect of perampanel (PER).

Aim. With the publication of a third treatment episode of EPC terminated by the administration of PER we would like to suggest that PER may be an effective treatment option in this condition.

Material and Methods. We present a case where PER was the last AED introduced in the treatment of a patient with EPC and individual seizures due to Rasmussen encephalitis before his seizure frequency could be reduced significantly.

Results. A 44 years old male patient, who had been on a combination therapy of at least 4 AEDs since the age of 24, was admitted to our hospital presenting with an EPC. After the introduction of PER in the therapy EPC stopped and he remained seizure free for more than a year. Two of his other AEDs could be tapered of.

Conclusion. PER might be especially effective in EPC.

Content not available PDF Share



Mameniskiene R., Bast T., Bentes C., Canevini M.P., Dimova P., Granata T. et al.: Clinical course and variability of non- Rasmussen, nonstroke motor and sensory epilepsia partialis continua: A European survey and analysis of 65 cases. Epilepsia, 2011, 52: 1168–1176.


Rajasekaran K., Joshi S., Kozhemyakin M., Todorovic M.S., Kowalsky S., Balint C., Kapur J.: Receptor trafficking hypothesis revisited: Plasticity of AMPA receptors during established status epilepticus. Epilepsia, 2013, 54 (Suppl. 6): 14–16.


Redecker J., Wittstock M., Benecke R., Rösche J.: Efficacy of perampanel in refractory nonconvulsive status epilepticus and simple partial status epilepticus. Epilepsy and Behavior, 2015, 45: 176–179.


Rohracher A., Höfler J., Kalss G., Leitinger M., Kuchukhidze G., Deak I. et al.: Perampanel in patients with refractory and super- refractory status epilepticus in a neurological intensive care unit. Epilepsy and Behavior, 2015, 49: 354–358.


Rösche J., Kampf C., Benecke R.: Possible effect of perampanel on focal status epilepticus after generalized tonic-clonic status epilepticus. Acta Neurologica Belgica, 2014, 114: 243–244.


Rösche J., Redecker J.: Treatment of status epilepticus – A narrative review on the evidence so far and a proposal for the design of retrospective studies. Eur. Med. Journ. Neurol., 2015, 3: 91–95.


Shorvon S., Baulac M., Cross H., Trinka E., Walker M.: The drug treatment of status epilepticus in Europe: Consensus document from a workshop at the first London Colloquium on Status Epilepticus. Epilepsia, 2008, 49: 1277–1284.


Steinhoff B.J.: Das neue Antiepileptikum Perampanel. Psychopharmakotherapie, 2012, 19: 202–208.


Trinka E., Hesdorfer D., Rossetti A.O., Scheffer I.E., Shinnar S. et al.: A definition and classification of status epilepticus – Report of the ILAE Task Force on Classification of Status Epilepticus. Epilepsia, 2015a, 56: 1515–1523.


Trinka E., Steinhoff B.J., Nikanorova M, Brodie M.J.: Perampanel for focal epilepsy: insights from early clinical experience. Acta Neurol. Scand., 2015b, DOI:10.1111/ane.12529


Varadkar S., Bien C.G., Kruse C.A., Jensen F.E., Bauer J., Pardo C.A. et al.: Rasmussen’s encephalitis: clinical features, pathobiology, and treatment advances. Lancet Neurology, 2014, 13: 195–205.


Watson R., Jiang Y., Bermudez I., Houlihan L., Clover L., McKnight K. et al.: Absence of antibodies to glutamate receptor type 3 (GluR3) in Rasmussen encephalitis. Neurology, 2004, 63: 43–50.